Register for email alerts and news feeds:
This journal | BMJ Group
rss
Journal of Clinical Pathology 2005;58:1064-1068; doi:10.1136/jcp.2004.023648
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

ORIGINAL ARTICLE

H19 expression in hepatic metastases from a range of human carcinomas

Y Fellig1, I Ariel1, P Ohana2, P Schachter3, I Sinelnikov4, T Birman2, S Ayesh2, T Schneider2, N de Groot2, A Czerniak3 and A Hochberg2

1 Department of Pathology, Hadassah Medical Organization, Ein-Kerem and Mount Scopus Branches, Jerusalem 91120, Israel
2 Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
3 Department of Surgery A, Wolfson Medical Center, Holon 58222, Israel
4 Department of Pathology, Soroka Medical Center, Beer-Sheva 84101, Israel

Correspondence to:
Correspondence to:
Dr Y Fellig
Department of Pathology, Hadassah Medical Organization, Kiryat Hadassah, PO Box 12000, Jerusalem 91120, Israel; fellig{at}hadassah.org.il

Aims: To investigate the expression of the imprinted oncofetal H19 gene in hepatic metastases derived from a range of human carcinomas and assess its prognostic value with the view of developing a DNA based treatment for such metastases.

Methods: Non-radioactive in situ hybridisation for H19 RNA was performed on paraffin wax embedded sections of liver biopsies or partial hepatectomy specimens, taken from 80 patients with hepatic metastases derived from carcinomas from several medical centres in Israel. The degree of expression was graded qualitatively according to the number of cells expressing H19 and the intensity of staining. The medical files were searched for demographic data and survival times before and after diagnosis of hepatic metastases.

Results: H19 expression was found in the hepatic metastases of 64 of 80 patients. High expression (higher staining grades) of H19 in the metastases was found in 43 of 80 patients. However, H19 expression status in the hepatic metastases did not correlate with either the length of time to development of metastasis or overall survival.

Conclusions: H19 is highly expressed in more than half of hepatic metastases derived from a range of carcinomas. Thus, these metastases may be suitable candidates for H19 DNA based treatment. Further studies are needed to determine whether H19 expression has prognostic value in metastatic liver disease using larger numbers of specific subtypes of primary carcinomas.

Abbreviations: CI, confidence interval; IGF, insulin-like growth factor

Keywords: H19 gene; hepatic metastases (from carcinomas); in situ hybridisation; DNA based therapy; prognostic value


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Pathology jobs

Pathology jobs